Literature DB >> 11746527

Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression.

S S Taneja1, S Ha, M J Garabedian.   

Abstract

To elucidate the mechanism of androgen-dependent cellular proliferation in prostate cancer, androgen-dependent alterations of individual cell cycle regulatory proteins in the androgen-sensitive prostate cancer cell line LNCaP were evaluated. LNCaP cells were deprived of androgens by culture in steroid-depleted media for 5 days, which resulted in the maximal accumulation of cells in G(0)/G(1) phase of the cell cycle. The mitogenic concentration of the synthetic androgen R1881 was established as 0.1 nM using cell proliferation assay. Protein and mRNA levels of particular cyclins, cyclin-dependent kinases (Cdks), cyclin-dependent kinase inhibitors (Ckis), and the retinoblastoma proteins (Rb) were assessed. Androgen stimulation resulted in a post-transcriptional reduction in Rb protein levels, an increase in Rb phosphorylation at serine 780 and an accumulation of high molecular weight Rb protein species. Androgen stimulation also induced the expression of the Cdk2 and Cdk1 as well as their regulatory partners, cyclin A and cyclin B, resulting in a corresponding increase in cyclin A/Cdk2 activity in vitro. Pulse-chase showed decreased Rb protein stability in androgen-treated LNCaP cells. Collectively, our findings suggest a novel mechanism of androgen-dependent prostate cancer growth in which androgen stimulation results in decreased Rb protein expression in LNCaP cells. The observation of decreased Rb protein stability in the setting of increased phosphorylation supports the concept of phosphorylation mediated protein degradation. We propose that the observed reduction in Rb protein level occurs through Rb degradation via the ubiquitin/proteasome pathway, and is preceded by selective Rb phosphorylation by cyclin A/Cdk2 and cyclin B/Cdk1. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746527     DOI: 10.1002/jcb.1278

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

2.  MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.

Authors:  T Sun; X Wang; H H He; C J Sweeney; S X Liu; M Brown; S Balk; G-Sm Lee; P W Kantoff
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

3.  The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.

Authors:  Sumudra Periyasamy; Manya Warrier; Manoranjani P M Tillekeratne; Weinian Shou; Edwin R Sanchez
Journal:  Endocrinology       Date:  2007-07-05       Impact factor: 4.736

4.  Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells.

Authors:  Young-Chae Kim; Congcong Chen; Eric C Bolton
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

5.  Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Authors:  Barbara Wegiel; Anders Bjartell; Johanna Tuomela; Nishtman Dizeyi; Martina Tinzl; Leszek Helczynski; Elise Nilsson; Leo E Otterbein; Pirkko Härkönen; Jenny Liao Persson
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

6.  The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.

Authors:  Zuzana Pernicová; Eva Slabáková; Radek Fedr; Šárka Šimečková; Josef Jaroš; Tereza Suchánková; Jan Bouchal; Gvantsa Kharaishvili; Milan Král; Alois Kozubík; Karel Souček
Journal:  Mol Cancer       Date:  2014-05-20       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.